MedTrace Logo

Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers

NCT05346601 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-02-09

No results posted yet for this study

Summary

The purpose of this study is to further study the pharmacokinetic characteristics of Chiauranib Capsule in Healthy Volunteers with High Fat Diet.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Chiauranib

50mg po only once

Sponsors & Collaborators

  • H & J CRO International, Inc.

    collaborator INDUSTRY

  • Chipscreen Biosciences, Ltd.

    lead INDUSTRY

Principal Investigators

  • LiYan Miao · First Affiliated Hospital of Suzhou Medical College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-02
Primary Completion
2022-06-28
Completion
2022-06-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05346601 on ClinicalTrials.gov